DelMar Pharmaceuticals, Inc. (DMPI)
Stock Price:
$1.29 USD
0.11 (8.90%)
Updated Aug 11, 2020 12:25 PM EDT - Market open
Key Info
| Market Cap |
14.72M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-7.89M |
| Shares Out |
11.46M |
| EPS (ttm) |
-0.95 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 11, 2020 |
| Last Price |
$1.29 |
| Previous Close |
$1.18 |
| Change ($) |
0.11 |
| Change (%) |
8.90% |
| Day's Open |
1.23 |
| Day's Range |
1.20 - 1.33 |
| Day's Volume |
1,202,841 |
| 52-Week Range |
0.38 - 2.45 |
More Stats
| Market Cap |
14.72M |
| Enterprise Value |
9.75M |
| Earnings Date (est) |
Sep 23, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
11.46M |
| Float |
10.64M |
| EPS (basic) |
-1.42 |
| EPS (diluted) |
-0.95 |
| FCF / Share |
-0.63 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
211,710 |
| Short Ratio |
0.32 |
| Short % of Float |
1.40% |
| Beta |
1.85 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
11.02 |
| Revenue |
n/a |
| Operating Income |
-8.28M |
| Net Income |
-7.89M |
| Free Cash Flow |
-7.16M |
| Net Cash |
4.97M |
| Net Cash / Share |
0.43 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-136.86% |
| ROE |
-316.72% |
| ROIC |
638.80% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (0)
| Buy |
0 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$3.00*
(133.46% upside)
Low
2.00
Current: $1.29
High
4.00
Target: 3.00
*Average 12-month price target from 2 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|
| Revenue | - | - | - | - | - |
| Operating Income | -8.40 | -11.17 | -8.32 | -6.21 | -4.72 |
| Net Income | -8.05 | -11.14 | -8.08 | -8.86 | -4.35 |
| Shares Outstanding | 2.57 | 2.09 | 1.20 | 1.09 | 0.95 |
| Earnings Per Share | -3.16 | -5.42 | -7.40 | -8.30 | -4.60 |
| Operating Cash Flow | -6.33 | -9.85 | -8.02 | -5.15 | -3.85 |
| Free Cash Flow | -6.33 | -9.85 | -8.02 | -5.15 | -3.85 |
| Cash & Equivalents | 3.72 | 5.97 | 6.59 | 6.16 | 1.75 |
| Net Cash / Debt | 3.72 | 5.97 | 6.59 | 6.16 | 1.75 |
| Assets | 4.04 | 7.07 | 7.91 | 6.36 | 2.58 |
| Liabilities | 2.07 | 1.64 | 1.33 | 1.50 | 3.40 |
| Book Value | 1.97 | 5.44 | 6.58 | 4.86 | -0.82 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
DelMar Pharmaceuticals, Inc. |
| Country |
United States |
| Employees |
2 |
| CEO |
Saiid Zarrabian |
Stock Information
| Ticker Symbol |
DMPI |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: DMPI |
Description
DelMar Pharmaceuticals, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. Its product candidate is VAL-083, a DNA-targeting agent, which is in Phase II clinical study for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma. The company has a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. to manufacture and sell VAL-083 in China; and Duke University to evaluate VAL-083 as a front-line treatment for newly diagnosed patients with GBM. DelMar Pharmaceuticals, Inc. was founded in 2009 and is headquartered in San Diego, California.